Mark Newman
Chief Tech/Sci/R&D Officer chez GEOVAX LABS, INC.
Fortune : - $ au 31/03/2024
Profil
Mark J.
Newman is the founder of Newmark Diagnostics LLC, which was founded in 2016.
He is currently the Chief Scientific Officer at GeoVax Labs, Inc. since 2020.
Dr. Newman is also a Member at Louisiana State University.
He received his undergraduate and graduate degrees from The Ohio State University and his doctorate from John Curtin School of Medical Research.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GEOVAX LABS, INC.
-.--% | 11/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Mark Newman
| Sociétés | Poste | Début |
|---|---|---|
| GEOVAX LABS, INC. | Chief Tech/Sci/R&D Officer | 25/08/2020 |
Anciens postes connus de Mark Newman
| Sociétés | Poste | Fin |
|---|---|---|
| GEOVAX LABS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2013 |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 28/04/2011 |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01/12/2009 |
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Chief Tech/Sci/R&D Officer | 01/12/2008 |
| Epimmune, Inc. | Chief Tech/Sci/R&D Officer | 01/12/2005 |
Formation de Mark Newman
| The Ohio State University | Graduate Degree |
| John Curtin School of Medical Research | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
| Epimmune, Inc. | Health Technology |
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
| GeoVax Labs, Inc. | |
| Newmark Diagnostics LLC |
